Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Retinoic Acid Syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12 result(s) found for: Retinoic Acid Syndrome. Displaying page 1 of 1.
    EudraCT Number: 2019-004019-29 Sponsor Protocol Number: CRACCA-2019 Start Date*: 2021-07-15
    Sponsor Name:Dipartimento di Medicina-DIMED, università di Padova
    Full Title: Medical combination therapy with retinoic acid and cabergoline in ACTH-secreting pituitary adenoma: a prospective and randomized study.
    Medical condition: Cushing's disease in patients in whom pituitary surgery has not been curative or in situations where it is contraindicated or refused by patient.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10011651 Cushing's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-004886-42 Sponsor Protocol Number: TRA114389 Start Date*: 2013-04-01
    Sponsor Name:University of Crete
    Full Title: Study of the effect of the thrombopoietin receptor agonist eltrombopag on thrombocytopenia and megakaryopoiesis of patients with lower and intermediate-1 risk myelodysplastic syndromes.
    Medical condition: Patients with lower and intermediate-1 risk myelodysplastic syndromes.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-015512-17 Sponsor Protocol Number: PMA112509 Start Date*: 2010-01-15
    Sponsor Name:GlaxoSmithKline
    Full Title: Study PMA112509, a Phase I/II Study of Eltrombopag in Thrombocytopenic Subjects with Advanced Myelodysplastic Syndrome (MDS) or secondary Acute Myeloid Leukemia after MDS (sAML/MDS)
    Medical condition: Advanced Myelodysplastic Syndrome (MDS) or secondary Acute Myeloid Leukemia after MDS
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028533 Myelodysplastic syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-003832-96 Sponsor Protocol Number: ChIm-NB-PL Start Date*: 2021-10-13
    Sponsor Name:Jagiellonian University Medical College
    Full Title: Immunotherapy with dinutuximab beta in combination with chemotherapy for the treatment of patients with primary neuroblastoma refractory to standard therapy and with relapsed or progressive disease
    Medical condition: Recurrent or progression of neuroblastoma or neuroblastoma refractory to first-line treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029260 Neuroblastoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066595 Neuroblastoma recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029261 Neuroblastoma NOS LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000550-75 Sponsor Protocol Number: RG_05-004 Start Date*: 2006-02-24
    Sponsor Name:University of Birmingham
    Full Title: Phase II Study of the Tolerability and Efficacy of the Histone Deacetylase Inhibitor Sodium Valproate given in Conjunction with 5-azacytidine and ATRA (all trans retinoic acid ) in Patients with Ac...
    Medical condition: Patients who have Acute Myeloid Leukaemia (AML) or Myelodysplasia (MDS) will be recruited to this trial
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028532 Myelodysplasia LLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-000497-30 Sponsor Protocol Number: FIS-VED-2017-01 Start Date*: 2018-05-28
    Sponsor Name:Fundación Pública Andaluza para la Gestión en Salud de Sevilla (FISEVI)
    Full Title: Phase II clinical trial to evaluate the safety and efficacy of Vedolizumab combined with antiretroviral treatment to achieve functional healing in people infected with HIV-1 without previous antire...
    Medical condition: Adult patients infected with HIV and without previous antiretroviral treatment.
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000783-14 Sponsor Protocol Number: SY-1425-201 Start Date*: 2017-10-27
    Sponsor Name:Syros Pharmaceuticals Inc.
    Full Title: A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
    Medical condition: Acute Myeloid Leukemia (AML)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-001856-36 Sponsor Protocol Number: RF-2016-02362383 Start Date*: 2018-08-07
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: A RANDOMIZED PHASE 2 CLINICAL TRIAL TO EVALUATE THE ACTIVITY OF ATRA IN COMBINATION WITH ANASTROZOLE IN PRE-OPERATIVE PHASE OF OPERABLE HR-POSITIVE/HER2-NEGATIVE EARLY BREAST CANCER EBC ATRA TRIAL
    Medical condition: Patients with newly, untreated, resectable HR+/HER2- eBCs, suitable for pre-operative therapy with anastrozole
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-000473-23 Sponsor Protocol Number: CULM20236 Start Date*: 2019-08-19
    Sponsor Name:OncoVerity Inc
    Full Title: A Phase 2 Study of Cusatuzumab Plus Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia who are not Candidates for Intensive Chemotherapy
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002822-19 Sponsor Protocol Number: B1371019 Start Date*: 2018-07-09
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A RANDOMIZED (1:1), DOUBLE-BLIND, MULTI-CENTER, PLACEBO CONTROLLED STUDY EVALUATING INTENSIVE CHEMOTHERAPY WITH OR WITHOUT GLASDEGIB (PF-04449913) OR AZACITIDINE (AZA) WITH OR WITHOUT GLASDEGIB IN ...
    Medical condition: ACUTE MYELOID LEUKEMIA
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) GB (GB - no longer in EU/EEA) CZ (Completed) SE (Completed) BE (Completed) PL (Completed) ES (Completed) DE (Completed) IT (Prematurely Ended) RO (Completed)
    Trial results: View results
    EudraCT Number: 2007-002183-99 Sponsor Protocol Number: INNO-507-P2 Start Date*: 2007-09-28
    Sponsor Name:INNOVIVE Pharmaceuticals
    Full Title: Un estudio de fase II de tamibaroteno en pacientes con leucemia promielocítica aguda que hayan recibido terapia previa con ATRA y trióxido de arsénico (STAR-1)
    Medical condition: Pacientes adultos con recidiva de leucemia promielocítica aguda (LPA) o leucemia promielocítica aguda refractaria después de haber sido tratados con ácido trans retinóico total (ATRA) y trióxido de...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001020 Acute promyelocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Ongoing) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-018077-31 Sponsor Protocol Number: 012010 Start Date*: 2010-11-25
    Sponsor Name:St. Anna Kinderkrebsforschung/CCRI
    Full Title: A PHASE I/II DOSE SCHEDULE FINDING STUDY FOR CH14.18/CHO CONTINUOUS INFUSION COMBINED WITH SUBCUTANEOUS ALDESLEUKIN (IL-2) IN PATIENTS WITH PRIMARY REFRACTORY OR RELAPSING NEUROBLASTOMA
    Medical condition: High-risk neuroblastoma patients having received at least one previous high dose treatment followed by stem cell rescue after conventional therapy fulfilling one of the following criteria: • Prima...
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Ongoing) ES (Ongoing) DE (Ongoing) IT (Ongoing) GB (GB - no longer in EU/EEA) IE (Ongoing) PL (Completed) BE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:02:26 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA